Dataset from A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects With Advanced Solid Tumor or Non-Hodgkins Lymphoma

This is a first time in human study that is being done to determine the maximum tolerated dose and initial pharmacokinetic parameters of GSK461364, given by IV, in adult subjects with solid tumors and Non-Hodgkins lymphoma.

本项正在开展的首次人体研究，旨在确定经静脉注射（IV）给予GSK461364的最大耐受剂量（maximum tolerated dose）与初始药代动力学参数，受试者为成人实体瘤及非霍奇金淋巴瘤（Non-Hodgkins lymphoma）患者。